Editorial Comment on FGFR3 Mutations and a

Editorial Comment on FGFR3 Mutations and a - [20 Van Oers...

Info iconThis preview shows page 1. Sign up to view the full content.

View Full Document Right Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: [20] Van Oers JMM, Lurkin I, van Exsel AJA, et al. A simple and fast method for the simultaneous detection of nine fibro- blast growth factor receptor 3 mutations in bladder cancer and voided urine. Clin Cancer Res 2005;11:7743–8. [21] Van Rhijn BW, van Tilborg AA, Lurkin I, et al. Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet 2002;10:819–24. [22] Harnden P, Allam A, Joyce AD, et al. Cytokeratin 20 expression by non-invasive transitional cell carcinomas: potential for distinguishing recurrent from non-recurrent disease. Histopathology 1995;27:169–74. [23] Alsheikh A, Mohamedali Z, Jones E, et al. Comparison of the WHO/ISUP classification and cytokeratin 20 expres- sion in predicting the behavior of low-grade papillary urothelial tumors. Mod Pathol 2001;14:267–72. [24] Quintero A, Alvarez-Kindelan J, Luque RJ, et al. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder. J Clin Pathol 2006;59:83–8. [25] Dyrskjøt L, Kruhøffer M, Thykjaer T, et al. Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathologi- cal classification. Cancer Res 2004;64:4040–8.cal classification....
View Full Document

{[ snackBarMessage ]}

Ask a homework question - tutors are online